Shares of Star Scientific (STSI -11.9%) crumble after the company is taken to task over...

Shares of Star Scientific (STSI -11.9%) crumble after the company is taken to task over allegedly misleading investors over its relationship with Johns Hopkins University. Despite claims to the contrary, the academic institution doesn't have any official involvement with Star Scientific or nutritional supplement anatabine, according to Adam Feuerstein.
From other sites
Comments (10)
  • liegh aulper
    , contributor
    Comments (231) | Send Message
    This story is bogus, the company never said it was a J H study. they made it clear it was a Roscamp study, in which some J H docs were involved. Adam should be ashamed of himself and it's obvious he never did any Due Diligence as he never quoted or cited any company statements.
    23 Jan 2013, 01:12 PM Reply Like
  • 174826
    , contributor
    Comments (4) | Send Message
    I have not seen anything from Star that states Johns Hopkins conducted the tests. A spokesman for Star is a Johns Hopkins staffer, and he has stated his positive opinions of the tests. Sounds like someone read too much into his credentials and tagged Johns Hopkins a role they aren't playing.


    This appears to be the beginning of a pump-and-dump in reverse.


    1. Trash the stock,
    2. Buy the stock.
    3. Pump the stock with a clarification of and apology for the original accusation.


    Wait and see. I'm guessing the accusers will begin pumping this stock in a few days. They should have all the shares they want by then.
    23 Jan 2013, 01:28 PM Reply Like
  • Labman01
    , contributor
    Comments (48) | Send Message
    They are exactly right! No one ever claimed John Hopkins Institute, itself was involved in the study. Several scientist that have done researched for J H are doing the study, and are also the ones that have presented evidence in front of the largest science gathering of it's kind. Have you ever looked at who has sat on the board of directors ? Have you read the connection with Harvard University and Star Scientific? There has never been one mention from John Hopkins except for their interest in the research results for the Thyroid study by the Roskamp Non-Profit Institute done by their own scientist that decided to look further into the discovery of Anatabine. The possitive results are already starting to snowball. As reported earlier, there are other large Pharma researchers that are now doing research with the permission of STSI. The talk has already started of these huge companies taking a better look at Star and what they have discovered.
    23 Jan 2013, 01:46 PM Reply Like
  • Labman01
    , contributor
    Comments (48) | Send Message
    One last thing that I was just informed of. When there is word or talk of something of interest that has been announced, an Institute like J H does not immediately start any research putting their name associated with any study, but they will sub out independent researchers to look further into what's being talked about that's so Interresting. The research will not be at the University in the beginning for obvious reasons. But I will say this, John Hopkins and several other institutes know exactly what's being found and any results that come in, they are looking very closely at, without putting their name to it yet.
    23 Jan 2013, 01:59 PM Reply Like
  • Labman01
    , contributor
    Comments (48) | Send Message
    To everyone that gets Seeking Alpha. Please look on the web under Star Scientific and Thyorid Study. No mention of The John Hopkins Institute. You are being taking for a ride by this person that has lied to you. What a cheap shot to short this stock!
    23 Jan 2013, 02:25 PM Reply Like
  • Goattime
    , contributor
    Comments (21) | Send Message
    Now what we all need is to have Daniel Loeb with Third Point LLC come in with a power point presentation. Bill Ackman can counter with a pro stance on STSI just opposite of Herbalife Days of our life stock. The big difference here is the price of the stock. STSI is penny stock that is fun to short or go long. Each article moves the stock enough to make money while having a good laugh. I have lost and won. Cheaper than Vegas!
    For all of us that haven't mastered grammar or spelling of the English Language, please use spell check so we look sharper than a dull pencil.
    23 Jan 2013, 02:59 PM Reply Like
  • MR-Tampa
    , contributor
    Comments (56) | Send Message
    This is how Star's press release introduces the Johns Hopkins employee: "Dr. Paul Ladenson, senior endocrinological consultant for the study, stated ...." so he was clearly presented as a "consultant" not as the Dr responsible for the study ...


    It looks like indeed the shorts are desperate to manipulate that share price down quickly ... do they fear more good news coming out soon I wonder ...
    23 Jan 2013, 03:58 PM Reply Like
  • 174826
    , contributor
    Comments (4) | Send Message
    The first comments I read that accused Star of misleading investors about its Johns Hopkins connection came from The Street (Jim Cramer's stock "advisory" business). Jim Cramer accusing someone of a falsehood is the ultimate "pot calling the kettle black". But you don't have to tell the truth to be a highly paid stock guru these days. My only complaint about pumper-dumpers is that they don't call me first. I'd like to get in on the action.


    Watch Star for a few days and decide for yourself if this whole Johns Hopkins story was prepping for a buying frenzy.
    23 Jan 2013, 03:59 PM Reply Like
  • The Lawman
    , contributor
    Comments (208) | Send Message
    Whether Dr. Ladenson was acting as a consultant for STSI, or on behalf of Johns Hopkins, is a red herring.


    If Ladenson and his unquestioned credentials and reputation stand behind the clinical study he conducted on anatabine, then Anatabloc has great promise.


    If Dr. Ladenson were to disavow this research, anatabine would be suspect.


    From what I have read, Dr. Ladenson not only stands behind his clinical study, but has characterized anatabine as a breakthrough in the treatment of thyroiditis.


    If the upcoming peer review of Dr. Ladenson's research study on anatabine bears out his conclusions, sales of Anatabloc will mushroom, and STSI will be off to the races, regardless of how Adam Feuerstein wishes to spin it.


    My bottom line is this:


    If I have to choose between an uninformed reporter with a potentially undisclosed short position, and one of the preeminent thyroid researchers in the world, I choose the latter.
    23 Jan 2013, 10:30 PM Reply Like
  • Beerguy
    , contributor
    Comment (1) | Send Message
    Just another example of some idiot not doing his "due diligence" on his reporting......trashing a stock to make a move in the market.....great for the shorts.....BS if you ask me. STSI is a "Buy" ......and long term.
    24 Jan 2013, 02:33 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs